Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

Pharmaceuticals Inc (SCPH) reports a 167% revenue growth and strategic advancements, despite facing increased expenses and ...

Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

Furoscix is a pH-neutral formulation of furosemide, a loop diuretic, designed for subcutaneous (SC) administration via a wearable, single-use, pre-programmed on-body infusor for outpatient ...

Scpharmaceuticals (SCPH) (ISIN: US8106481059)股票专题，提供今日Scpharmaceuticals(SCPH) (ISIN: US8106481059)股票最新股价查询，实时市场行情，走势图表，及Scpharmaceuticals Inc(SCPH) (ISIN: ...

Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure.

Cardiorenal specialist scPharmaceuticals has won US Food and Drug Administration (FDA) approval for its supplemental New Drug Application (sNDA) for Furoscix (furosemide injection) to expand the ...

周五，H.C. Wainwright & ...

(SCPH) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for FUROSCIX to expand the indication to include treatment of edema in ...